Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 mutation-related disease and thrombosis.

Seminars in thrombosis and hemostasis - 1 Jul 2013

Vannucchi Alessandro M, Guglielmelli Paola

Abstract excerpt

A recurrent JAK2V617F mutation is typically associated with chronic myeloproliferative neoplasms (MPNs) that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis. This mutation results in a gain of function that is credited to underlie most of the pathogenesis and phenotypic characteristics of these disorders; it serves as a key diagnostic marker and represents a suitable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Models, Genetic
Share to JAK2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Risk Factors

Share to Signal Transduction

Share to Thrombosis

Source

Identifiers

PMID: 23633193
DOI: 10.1055/s-0033-1343890

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 mutation-related disease and thrombosis.PMID 23633193Read ↗

JAK2 mutation and thrombosis in the myeloproliferative neoplasms.Semantic proximity Read ↗

Thrombocytosis and thrombosis.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

Molecular biomarkers of thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS scoreSemantic proximity Read ↗

Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision OncologySemantic proximity Read ↗

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].Semantic proximity Read ↗

New advances in the pathogenesis and therapy of essential thrombocythemia.Semantic proximity Read ↗

[Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].Semantic proximity Read ↗

[Thrombosis in myeloproliferative neoplasms].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.